References
- Mannucci PM, Tuddenham EG. The hemophilias‐ from royal genes to gene therapy. N Engl J Med. 2001;344:1773–1779. doi:https://doi.org/10.1056/NEJM200106073442307.
- Aznar JA, Magallón M, Querol F, Gorina E, Tusell JM. The orthopaedicstatus of severe haemophiliacs in Spain. Haemophilia. 2000;6:170–176. doi:https://doi.org/10.1046/j.1365-2516.2000.00397.x.
- Rendo P, Shafer F, Korth‐Bradley JM, Sivamurthy K, Korin J. Factorsthat influence the bleeding phenotype in severe hemophilic patients. Blood Coagul Fibrinolysis. 2013;24:683–690. doi:https://doi.org/10.1097/MBC.0b013e3283614210.
- Ninivaggi M, Dargaud Y, van Oerle R, de Laat B, Hemker HC, Lindhout T. Thrombin generation assay using factor IXa as a triggerto quantify accurately factor VIII levels in haemophilia A. J Thromb Haemost. 2011;9:1549–1555. doi:https://doi.org/10.1111/j.1538-7836.2011.04358.x.
- Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6‐year follow‐up of dosing, coagulation factor levels and bleedings in relation to join tstatus in the prophylactic treatment of haemophilia. Haemophilia. 2004;10:689–697. doi:https://doi.org/10.1111/j.1365-2516.2004.01036.x.
- Broze GJ.Jr. Thrombin‐dependent inhibition of fibrinolysis. Curr Opin Hematol. 1996;3:390–394.
- Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler ThrombVasc Biol. 2000;20:2511–2518. doi:https://doi.org/10.1161/01.atv.20.12.2511.
- Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood. 2003;101:4844–4846. doi:https://doi.org/10.1182/blood-2002-09-2944.
- Wyseure T, Cooke EJ, Declerck PJ, et al. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. Blood. 2018;132(15):1593–1603. doi:https://doi.org/10.1182/blood-2018-01-828434.
- Urano T, Castellino FJ. Suzuki YRegulation of plasminogen activation on cell surfaces and fibrin. J Thrombosis Haemostasis JTH. 2018;16(8):1487–1497.
- Hosokawa K, Ohnishi‐Wada T, Sameshima‐Kaneko H, et al. Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in‐vitro flow chamber model. Thromb Res. 2016; 146:69–75. doi:https://doi.org/10.1016/j.thromres.2016.09.002.
- Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet‐released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet‐fibrin thrombus. Blood. 1993;81:1290–1299. doi:https://doi.org/10.1182/blood.V81.5.1290.1290.
- Van De Craen B, Declerck PJ, Gils A. The biochemistry, physiology and pathological roles of PAI-1 and the requirements forPAI-1 inhibition in vivo. Thromb Res. 2012;130(4):576–585. doi:https://doi.org/10.1016/j.thromres.2012.06.023.
- Mehta R, Shapiro AD. Plasminogen activatorinhibitor type 1 deficiency. Haemophilia. 2008;14(6):1255–1260. doi:https://doi.org/10.1111/j.1365-2516.2008.01834.x.
- Kolev K, Longstaff C. Bleeding related to disturbed fibrinolysis. Br J Haematol. 2016;175(1):12–23. doi:https://doi.org/10.1111/bjh.14255.
- Semeraro F, Mancuso M, Ammollo C, et al. Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A. J Thromb Haemost. 2019;00:1–9.
- Mosnier LO, Lisman T, den Berg v, Nieuwenhuis HM, MeijersJC HK, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost. 2001;86:1035–1039. doi:https://doi.org/10.1055/s-0037-1616530.
- Antovic J, Schulman S, Eelde A, et al. Total thrombin activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. Haemophilia. 2001;7:557–560. doi:https://doi.org/10.1046/j.1365-2516.2001.00571.x.
- GrüNewald M, Siegemund A, Grünewald A, Konegan A, Koksch M, Griesshammer M. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia. 2002;8:768–775. doi:https://doi.org/10.1046/j.1365-2516.2002.00686.x.
- Antovic JP, Schulman S, An SS, Greenfield RS, Blombäck M. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? Scand J Clin Lab Invest. 2004;64:745–751. doi:https://doi.org/10.1080/00365510410003093.
- Mikovic D, Pruner I, Antovic JP, Chaireti R. Presence of thrombophilia and levels of coagulation factors, coagulation inhibitors and TAFI do not affect global haemostasis or bleeding phenotype in patients with haemophilia A. Thromb Res. 2019;173:1–3. doi:https://doi.org/10.1016/j.thromres.2018.11.008.
- Chetaille P, Alessi MC, Kouassi D, et al. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost. 2000; 83:902–905. doi:https://doi.org/10.1055/s-0037-1613941.
- Abdul S, Boender J, Malfliet J, et al. Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease. Haemophilia. 2017;23:437–443. doi:https://doi.org/10.1111/hae.13206.
- Agren A, Wiman B, Stiller V, et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost. 2006; 4:201–208. doi:https://doi.org/10.1111/j.1538-7836.2005.01709.x.
- Hvas A-M, Sørensen HT, Norengaard L, Christiansen K, Ingerslev J, Sørensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost. 2007;5:2408–2414. doi:https://doi.org/10.1111/j.1538-7836.2007.02755.x.